1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. SHILPA MEDICARE LTD.
Shilpa Medicare Ltd.
NSE: SHILPAMED | BSE: 530549|ASM

Shilpa Medicare Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 2 Starfolio Baskets
aboutShilpa Medicare Ltd. is a vertically integrated pharmaceutical company headquartered in Raichur, Karnataka. Established in 1987, the company has evolved from an API manufacturer into a specialist drug delivery entity with a diversified presence in on... Read More
ANDA Approvals
Ask AI about Shilpa Medicare
924.55-31.05(-3.25%)

256.28% Gain from 52W Low

629.6K
NSE+BSE Volume

NSE 02 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Shilpa Medicare is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
59.0 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

20

S

6

W

3

O

2

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive8Negative

Pass in checklist65.2%

045
55
100

PE Valuation Check

Right Now
Undervalued
61.8%
1 Year Forward
Undervalued
59.4%
INSIGHTShilpa Medicare is undervalued at both current PE and future earnings estimates.

Shilpa Medicare Stock Price Analysis

Day Price Range

-3.2% 1 Day return
924.6 (LTP)
916.2961
LowHigh

Week Price Range

7.0% 1 Week return
924.6 (LTP)
860979.8
LowHigh

Month Price Range

-13.1% 1 Month return
924.6 (LTP)
820.41,086.8
LowHigh

52 Week Price Range

162.0% 1 Year return
924.6 (LTP)
259.51,095
LowHigh
View full Price History/Seasonality

Shilpa Medicare Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Inline

Shilpa Medicare's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

CURRENT EPS
12.4
AVG. ESTIMATE
15
LOW ESTIMATE
13.2
HIGH ESTIMATE
16.4
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 20.4% in FY27

Consensus Recommendation

4 ANALYST Recommendations
BUY

The consensus recommendation from 4 analysts for Shilpa Medicare is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Shilpa Medicare Technical Analysis

Shilpa Medicare EMA & SMA

Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
5 Day927.6
10 Day925.6
12 Day928.2
20 Day938.6
26 Day941
50 Day913.3
100 Day813.4
200 Day673.6

Shilpa Medicare Delivery And Volume

Daily Avg. Delivery Volume %
02 Nov, 202648.9%
Week44.3%
Month46.9%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Shilpa Medicare Resistance and Support

933.93
Pivot
First Resistance951.6
Second Resistance978.7
Third Resistance996.4
First Support906.9
Second Support889.2
Third Support862.1
Day RSI47.2
Day MACD-12.8
Day MFI47.1
Day MACD Signal Line-11.5

Shilpa Medicare Beta

1 Month0.4
1 Year0.8
3 Month0.4
3 Year1.0

Shilpa Medicare Price Change Analysis

↓-13.1%
Over 1 Month
LowHigh
820.41086.8
↑51.3%
Over 3 Months
LowHigh
614.11095
↑127.4%
Over 6 Months
LowHigh
408.11095
↑162.0%
Over 1 Year
LowHigh
259.51095
All Technicals →

Shilpa Medicare Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Vishnukant Chaturbhuj BhutadaPromoter12,731,2206.5 %
Cohesion Mk Best Ideas Sub-TrustFii4,054,9732.1 %
Suraj Kumar InaniPublic7,841,3904.0 %
Sbi Life Insurance Co. LtdDii5,015,5422.6 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Shilpa Medicare Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
MICROCURVES TRADING PRIVATE LIMITEDBulkSell06 Aug 2026760.041,077,507NSE
MICROCURVES TRADING PRIVATE LIMITEDBulkPurchase06 Aug 2026759.361,077,507NSE
MICROCURVES TRADING PRIVATE LIMITEDBulkSell05 Aug 2026723.161,103,058NSE
MICROCURVES TRADING PRIVATE LIMITEDBulkPurchase05 Aug 2026722.791,103,058NSE
THE VANGUARD GROUP INC AC VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUNDBulkPurchase21 Mar 2025683.03547,853NSE
UBS PRINCIPAL CAPITAL ASIA LIMITEDBlockSell23 Jan 2025818.05163,006NSE
UBS AGBlockPurchase23 Jan 2025818.05163,006NSE
PLUTUS WEALTH MANAGEMENT LLPBulkPurchase05 Jun 2024492.34750,000NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell21 Feb 2024444.09482,523NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase21 Feb 2024443.95482,523NSE
All deals
All insider trades

Shilpa Medicare Corporate Actions

Shilpa Medicare Dividend history and yield

Shilpa Medicare dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Shilpa Medicare dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
104 Sep 2026
0.6FINAL04 Sep 2026Equity Share
217 Sep 2025
1FINAL17 Sep 2025Equity Share
319 Sep 2022
1.1FINAL-Equity Share
420 Sep 2021
1.1FINAL-Equity Share
516 Mar 2020
1.1INTERIM17 Mar 2020Equity Share

Shilpa Medicare Bonus shares

Shilpa Medicare bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
103 Oct 2025
1:103 Oct 2025
216 Jul 2013
1:2-

Shilpa Medicare Board Meetings

Shilpa Medicare past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
205 Aug 2026
Quarterly Results-
322 May 2026
Audited Results & Dividend-
406 Feb 2026
Quarterly Results-
513 Nov 2025
Quarterly Results-

Shilpa Medicare Stock Split

Shilpa Medicare stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
106 Nov 2015
21-
228 Sep 2007
10208 Oct 2007
All Corporate Actions

Shilpa Medicare Research Reports

Shilpa Medicare research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
106 Apr 2026Ventura511391.35Buy30.57%136.25%pdf
214 Nov 2022ICICI Securities Limited
Reco
292288.55Hold1.2%220.41%pdf
324 Aug 2022ICICI Securities Limited346391.05Sell-11.52%136.43%pdf
414 Aug 2022ICICI Securities Limited346397Sell-12.85%132.88%pdf
510 Apr 2022Monarch Networth Capital Limited645496.65Buy29.87%86.16%pdf
All Reports of Shilpa

Shilpa Medicare Corporate Filings

Shilpa Medicare BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
29 Oct 2026
Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor conference call for Q2-FY27 is scheduled to be held on 05 November 2026.
PDF
29 Oct 2026
Shilpa Medicare Ltd - 530549 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30 September, 2026.
Shilpa Medicare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone & Consolidated) for the 2nd Quarter and Half year ended 30 September, 2026.
PDF
10 Oct 2026
Shilpa Medicare Ltd - 530549 - Europe GMP Approval Of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana.
Europe GMP approval of Shilpa Medicare Limited. Unit 4, Jadcherla, Telangana.
PDF
07 Oct 2026
Shilpa Medicare Ltd - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018
PDF
26 Sep 2026
Shilpa Medicare Ltd - 530549 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 26, 2026 for Ramakant Innani & Others
PDF
VIEW ALL

Shilpa Medicare DocumentsAsk MarketMind AI

Shilpa Medicare Earnings Call

Shilpa Medicare earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
10 Aug 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
26 May 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
22 May 2026Shilpa Medicare Results Earnings Call for Q4FY26 & Full YearAudioVideo
10 Feb 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
19 Nov 2025Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Shilpa Medicare Annual Reports

Shilpa Medicare financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Shilpa Medicare Credit Ratings

Shilpa Medicare credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
05 Jul 2026india ratingsIndia Ratings Upgrades Shilpa Medicare’s Bank Facilities to ‘IND AA-’/StableLink
30 Jun 2025india ratingsIndia Ratings Revises Outlook on Shilpa Medicare’s Bank Facilities to Positive; Affirms ‘IND A+’Link
22 Nov 2023india ratingsCorrection: India Ratings Affirms Shilpa Medicare at ‘IND A’/Negative; Off Rating Watch with Negative ImplicationsLink
24 Jul 2023india ratingsIndia Ratings Affirms Shilpa Medicare at ‘IND A’/Negative; Off Rating Watch with Negative ImplicationsLink
26 Mar 2023india ratingsIndia Ratings Downgrades Shilpa Medicare to ‘IND A’; Places on Rating Watch with Negative ImplicationsLink

Shilpa Medicare Investor Presentations

Shilpa Medicare investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
05 Aug 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
22 May 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Feb 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Feb 2026Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationLink
13 Nov 2025Shilpa Medicare Ltd - 530549 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Shilpa Medicare - Company Profile

Shilpa Medicare Management Structure

Shilpa Medicare management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Alpesh DalalChief Financial Officer34.39Mar 26
Ritu TiwaryCompany Secretary,Compliance Officer10.98Mar 26
Keshav BhutadaExecutive Director,Chief Executive Officer-Mar 26
Dr. Vellaian KaruppiahChief Operating Officer-Mar 26
Dr. Uday HarleChief Executive Officer-Mar 26

Shilpa Medicare Board of Directors

Shilpa Medicare Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Vishnukant BhutadaED / MD / Promoter350Mar 26
Sharath Reddy KalakotaE D & Wholetime Director199.51Mar 26
Hetal GandhiIndependent Non Exe. Director60Mar 26
Ashraf Loutfy Abdelhamid AllamIndependent Non Exe. Director22.2Mar 26
Anita BandyopadhyayIndependent Non Exe. Director18Mar 26
Omprakash InaniChairman & Non Executive Dir.4.5Mar 26
Ritu TiwaryCompany Sec. & Compli. Officer-Mar 26
Website: www.vbshilpa.com

About the company - Business Profile

Shilpa Medicare Ltd. is a vertically integrated pharmaceutical company headquartered in Raichur, Karnataka. Established in 1987, the company has evolved from an API manufacturer into a specialist drug delivery entity with a diversified presence in oncology, non-oncology, biologics, and emerging specialty segments like Antibody Drug Conjugates (ADCs). The company operates across more than 50 countries, with a significant regulatory footprint in the US, EU, and emerging markets.

Key Points

Key Facts

  • Founded Year: 1987
  • Headquarters: Raichur, Karnataka, India
  • Stock Listing: NSE (SHILPAMED) and BSE
  • Core Products: Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (injectables, oral solids, films, and patches), and Biologics.

Operations and Resources

  • Manufacturing Facilities: Operates over 10 regulatory-approved manufacturing and R&D facilities.
    • API Units: Two facilities in Raichur (Unit-1 and Unit-2) with a total reactor capacity exceeding 1,000 KL.
    • Formulations: Located in Jadcherla (Hyderabad) and Dabaspet (Bengaluru). The Jadcherla unit specializes in oncology injectables and oral solids.
    • Biologics: A dedicated facility situated at Dharwad.
  • R&D Strength: Employs over 400 R&D personnel across five research centers in Karnataka, Telangana, and Gujarat. The company has filed over 550 patent applications globally.

Business Model and Market Significance

  • Model: Primarily operates on a Business-to-Business (B2B) model, providing APIs and Contract Development and Manufacturing Organization (CDMO) services, while also moving into proprietary specialty formulations.
  • Strategic Importance: The company is a key player in the oncology segment and is expanding into New Drug Delivery Systems (NDDS) and high-growth areas like GLP-1 peptides (Liraglutide and Semaglutide).
  • Recent Milestone: Launched NorUDCA (Nor-Ursodeoxycholic Acid), a first-in-class treatment for Non-alcoholic Fatty Liver Disease (NAFLD) in India.

Revenue and Financial Overview (FY2024-25)

  • Total Revenue: Rs 1,309.56 crore (FY25), representing a 13% growth over the previous year.
  • EBITDA: Rs 340.21 crore with an EBITDA margin of approximately 26%.
  • Revenue Breakdown by Segment (FY25):
    • APIs: 56%
    • Formulations: 36%
    • Biologics: 2%
    • Other: 6% (Includes CDMO, Polymers, and others)
  • Geographical Presence: The company serves clients in over 50 countries, with significant revenue contributions from India, the US, and Europe.
  • 9M FY2025-26 Performance: For the nine-month period ending December 2025, revenue reached Rs 1,110 crore (+14% YoY) and EBITDA stood at Rs 323 crore (+26% YoY).

Strategic Initiatives and Innovation

  • Biologics and ADCs: Focus on developing recombinant human albumin and mammalian products.
  • Peptides: Supplying initial quantities of new peptide projects to MNCs and readying DMFs for GLP-1 products.
  • CDMO Expansion: Increasing focus on high-margin CDMO projects for global pharmaceutical partners.
  • Regulatory Filings: Cumulative filings include 45 US DMFs and 60 EU/EMEA filings as of March 2025. Unit-1 and Unit-2 recently cleared audits from ANVISA (Brazil) and COFEPRIS (Mexico).

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Shilpa Medicare FAQ

Shilpa Medicare today is trading in the red, down by 3.25% at ₹924.55.
Shilpa Medicare is currently trading down 3.25% on an intraday basis. In the past week the stock rose 6.97%. Stock has been up 51.26% in the past quarter and rose 162.02% in the past year. You can view this in the share price history/seasonality section.
Shilpa Medicare is listed on NSE with the ticker SHILPAMED and on BSE as 530549. It's currently trading on NSE at a share price of ₹924.55 and on BSE with a share price of ₹929.15.
The market cap of Shilpa Medicare is ₹18,082.52 Cr. as of Nov 02, 2026.
Shilpa Medicare announced a FINAL dividend of 60% which equals ₹0.6 in Sep 04, 2026.The last three ex-dates for Shilpa Medicare were Sep 17, 2025, Sep 19, 2022 and Sep 20, 2021. To view the full dividend history of Shilpa Medicare click here.
Shilpa Medicare has undergone 2 stock splits and announced bonus shares 2 times since its BSE/NSE listing. The latest announcement for Shilpa Medicare stock split was on Nov 06, 2015 at a ratio of 2:1 and the last bonus share announcement was on Oct 03, 2025 at a ratio of 1:1.
Shilpa Medicare reported ₹468.91 Cr. in revenue, ₹100.88 Cr. in net profit, and ₹139.39 Cr. in EBITD as of Aug 05, 2026 for Q1 FY26-27.
According to the predictions of 4 analysts, the share price prediction for Shilpa Medicare is ₹881.25 with a downside of 5%.
The PE ratio of Shilpa Medicare is 60.82 as of Nov 02, 2026.
The PB ratio of Shilpa Medicare is 6.73 as of Nov 02, 2026.
You can view the latest analyst reports on the Shilpa Medicare reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×